NASDAQ:NKTR Nektar Therapeutics Q2 2026 Earnings Report $70.68 -0.09 (-0.13%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$69.72 -0.96 (-1.35%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Nektar Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$1.94Beat/MissN/AOne Year Ago EPSN/ANektar Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$10.43 millionBeat/MissN/AYoY Revenue GrowthN/ANektar Therapeutics Announcement DetailsQuarterQ2 2026Date8/6/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Nektar Therapeutics Earnings HeadlinesNektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial MarketsJuly 28 at 6:00 PM | prnewswire.comNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 24, 2026 | prnewswire.comThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.July 30 at 1:00 AM | Porter & Company (Ad)Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Moderate Buy" by BrokeragesJuly 23, 2026 | americanbankingnews.comNektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisJuly 21, 2026 | prnewswire.comNektar’s Phase 3 Eczema Bet: What Rezpegaldesleukin Could Mean for NKTR StockJuly 17, 2026 | tipranks.comSee More Nektar Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nektar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nektar Therapeutics and other key companies, straight to your email. Email Address About Nektar TherapeuticsNektar Therapeutics (NASDAQ:NKTR) (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases. Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs. Notable examples are NKTR-214 (bempegaldesleukin), an immuno-oncology agent designed to stimulate T-cell and natural killer cell activity in combination with checkpoint inhibitors, and NKTR-255, an IL-15 receptor agonist intended to enhance immune responses in oncology and infectious diseases. The company’s earlier polymer conjugate derivative of irinotecan, etirinotecan pegol, was licensed to a global partner for the treatment of metastatic breast cancer, underscoring Nektar’s expertise in drug delivery innovation. Founded in 1990 and headquartered in San Francisco, Nektar operates research and development facilities in the United States and collaborates with international pharmaceutical companies to advance its pipeline. Its partnerships have included agreements with Bristol-Myers Squibb and AstraZeneca, reflecting a strategy of combining its novel molecules with established therapies to maximize patient benefit. Under the leadership of President and Chief Executive Officer Howard W. Robin, Nektar continues to invest in its core technology platforms. The management team brings deep experience in biopharmaceutical development, clinical operations and global regulatory affairs, positioning the company to progress multiple candidates through clinical trials and toward potential regulatory approval.View Nektar Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why SK hynix Could Be the Best AI Chip Stock to Buy NowWhy Bloom Energy May Be the Most Important AI Infrastructure StockAlphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?Seagate Technology Stock Surges as Earnings Beat Silences AI DoubtersCarrier Earnings Could Send the Stock to a New All-Time High3 Refiners Benefiting From Oil Volatility and Tight Fuel SupplyWelltower at 52-Week Highs—But Analysts Believe There's More to Come Upcoming Earnings Linde (7/31/2026)Keysight Technologies (7/31/2026)Colgate-Palmolive (7/31/2026)Chevron (7/31/2026)Enbridge (7/31/2026)ExxonMobil (7/31/2026)NatWest Group (7/31/2026)Sumitomo Mitsui Financial Group (7/31/2026)Eaton (7/31/2026)AbbVie (7/31/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
